theMednet Community Answers: ASCO 2020

The American Society of Clinical Oncology (ASCO) annual meeting brings top oncology experts, physicians, and community members from around the world to discuss the latest research and breakthroughs in cancer. Though ASCO 2020 went virtual for the first time in its history, the landmark annual meeting still produced findings and updates on long-awaited studies and research in the world of oncology. Just because ASCO is over, doesn't mean the discussion has to end! Below you'll find theMednet community of experts answering questions related to ASCO 2020.

If you have a question about ASCO 2020, ask it on the theMednet and some of our 900 experts will weigh in!  

Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFR+ NSCLC given data presented at ASCO 2020?

Will you offer capecitabine for 1 year to all localized TNBC patients based on the SYSUCC-001 trial presented at ASCO?

In light of DESKTOP III, how will you approach secondary debulking for platinum sensitive epithelial ovarian cancer patients?

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

Which patients would you treat with relugolix instead of injectable GnRH agonist therapy?

For muscle invasive bladder cancer, after neoadjuvant chemotherapy with cis/gem and surgery with residual tumor and lymph node involvement, would you consider adjuvant avelumab as an extrapolation base on the JAVELIN 100 results?

How do you stage patients with testicular cancer who may have CSIS disease?

How do you counsel patients and caregivers regarding management of cancer-associated cachexia?

What is your current practice for obtaining mutation status for a patient with newly diagnosed ovarian cancer?